Background: The use of in vitro cell cultures is a powerful tool for obtaining key insights into the behaviour and response of cells to interventions in normal and disease situations. Unlike in vivo settings, in vitro experiments allow a fine-tuned control of a range of microenvironmental elements independently within an isolated setting.
| BACKGROUND AND RATIONALE
Mammalian tissues are highly complex microenvironments where a close interplay exists between the cellular and acellular compartments. [1] [2] [3] [4] This complex and reciprocal interaction is technically challenging to reproduce in vitro as both healthy and diseased tissues co-evolve over time. Furthermore, in vivo study of these complex tissue environments is time-consuming and labour intensive, and experimental manipulation is typically limited. 5, 6 Two-dimensional (2D) in vitro culture models represent the mainstay of the majority of cell biology. Whilst these models have resulted in the vast knowledge accumulated over the past decades, it is now becoming increasingly apparent that data generated in these models typically do not extrapolate to the three-dimensional (3D) setting. 5 There are several reasons for this: 2D plastic surfaces are much stiffer in comparison to most tissues except bone and so do not capture the biomechanics of native tissue environments; 2D tissue culture also lacks the complex heterogeneous 3D nature of the Extracellular matrix (ECM), where extrinsic cues and clues are presented on nanoscopic, microscopic, and macroscopic scales to cells. Cell behaviour and phenotype are the complex integration of collective nonlinear interactions between cellular and environmental cues. 7 Cells within 3D environments continually assimilate and process the information received leading to alterations in their intracellular signalling that governs cell fate. 8 2D culture therefore cannot replicate crucial spatial compartmentalization of extrinsic signalling cues which constitutes a fundamental feature of the 3D ECM landscape and underpins the very essence of tissue and organ complexity. 9 As a result, in the last few decades, there has been an explosion in the emergence of novel approaches to produce more physiologically relevant and tuneable 3D cultures, increasing not only the fidelity of these models, but also dramatically improving our ability to monitor and image cellular response enabling real-time study. 5, [10] [11] [12] [13] [14] Within these models, genetic, epigenetic, immunological, and chemical perturbation of malignant and nonmalignant cells and tissues can be tested against carefully controlled microenvironmental factors such as oxygen tension, pH, reactive oxygen species, growth factors as well as ECM biochemistry and biomechanics. These approaches are slowly bridging the gap between complex in vivo experiments and in vitro experiments.
They allow us to answer not only key biological questions, but more importantly in disease models, it allows us to rapidly and reliably screen and test novel therapeutic approaches to increase the fidelity of preclinical portfolios. One caveat, however, is that many of these 3D in vitro model systems are time-consuming and work-intensive with often limited scalability. Thus, the miniaturisation and integration of organotypic culture models into high-throughput assays can lead to the rapid evaluation of novel drugs in a cost-effective and timeeffective manner. [15] [16] [17] [18] From a clinical perspective, a cost-efficient protocol to validate drug efficacy in ex vivo patient-derived transplants could facilitate personalised decision making in oncology. [19] [20] [21] Extracellular matrix deposition, contraction, and remodelling are common to diseases such as tissue fibrosis, diabetes, and tissue aging and importantly are salient features of almost all solid tumours. 3, 22 Prior to and during malignant transformation and tumour expansion, the host stroma typically initiates a desmoplastic stromal response. 1, [23] [24] [25] [26] This response leads to a significant deposition and remodelling of the ECM within and surrounding the tumour. Whilst still the topic of much debate as to the precise antitumourigenic and/or protumourigenic properties of this fibrotic reaction, it ultimately leads to a significantly altered tumour microenvironment both biochemically and biomechanically. [27] [28] [29] [30] [31] The response is manifested by the presence of activated fibroblasts, either resident or recruited to the site of the developing tumour. 1, 2, [32] [33] [34] [35] [36] [37] [38] These fibroblasts have been shown to be the major source of tumour desmoplasia, by secreting and remodelling ECM components including collagens. These cancer-associated fibroblasts (CAFs) are now seen as critical in the progression of many solid tumours. 2, 25, 32, 37, [39] [40] [41] Thus, given the critical importance of these stromal cells in tumour onset and progression, their inclusion in 3D cancer models is of utmost importance.
Here, we describe a modified organotypic assay, the "Mini-Organo," that adapts and improves previously published protocols 10,42-44 by significantly reducing the time for contraction and invasion to occur, so that it can be quickly scaled for large-scale drug testing and completed within 5 days. We demonstrate its application in a wide range of mouse and human cancer biology approaches including evaluation of stromal cell (CAF) 3D ECM remodelling, 3D cancer cell (CC) invasion, and the assessment of potential anticancer therapeutic targets. Furthermore, the Mini-Organo assay described is highly amenable to customisation using different cell types under diverse experimental conditions and so can easily be adopted to noncancer studies. An overview of the workflow for the Mini-Organo is shown in Figure 1 .
| MATERIALS AND EQUIPMENT REQUIRED AND REAGENT SETUP

| Preparation of native acid-extracted collagen source (yields approx. 1 g of purified Collagen I)
This step details the in-house extraction and preparation of large batches of high quality Collagen type I (hereafter "collagen I") for use in the Mini-Organos. It is not necessary to extract fresh collagen I for every experiment, and batches of extracted collagen can be sterilised and stored at 4°C for several months. If a suitable collagen I source is in place, steps 2a and 3a can be omitted. The "5-day"
Mini-Organo does not include the generation of a stock collagen solution; however, for completeness, we have included this step.
Here, we describe a protocol for extracting collagen I from rat tails, although other alternative methodologies and sources may be used. 10, 42, 45 • 12 to 14 tails from rats of any age and/or strain. • Filter paper (Chux, Whattman, or coffee filters-any sturdy filter paper for filtering out insoluble tail sheath).
• Cooled centrifuge with~200-mL capacity buckets.
• Toothed forceps.
• Scalpels (no. 22.)
• Dialysis tubing 14 000 MWCO • Sodium chloride (NaCl) salt. 
| Cell culture
• Fibroblasts of interest, ie, cancer-associated fibroblasts (CAFs) including predetermined optimal growth medium and incubation conditions. The choice of CAF used will affect the degree of contraction and also invasion. The number of CAFs and length of time for contraction of the matrices will need to be optimised for each CAF line used (described later).
○ In this work, we demonstrate ECM remodelling using the following CAF lines. "HN-CAFs" are derived from a human head and neck carcinoma, "V-CAFs" are derived from a human vulval carcinoma, and "Cer-CAFs" are derived from a human cervical carcinoma.
All human CAFs (HN-V-and Cer-CAFs) were collected from fresh patient tissue under approved ethical review and immortalised using the hTERT lentivirus. Further information and characterisation of these human CAFs have previously been published. [48] [49] [50] [51] Human CAFs are grown in DMEM with high glucose, 10% fetal bovine serum, and penicillin-streptomycin (10 000 U/ mL penicillin G sodium and 10 000 μg/mL streptomycin sulphate) and supplemented with Gibco Insulin-Transferrin-Selenium (1×) solution. Cells are cultured at 37°C in a humidified incubator in atmospheric O 2 supplemented with 5% CO 2 .
All cell lines were regularly tested for mycoplasma and for murine pathogens by IMPACT testing (IDEXX Laboratories, Inc.).
Reagents required
• 0.25%trypsin-EDTA.
• 1x phosphate buffered saline (PBS).
• Trypan blue for cell counting (0.4% stock solution).
• Cell strainers (100, 70, and 40 micron).
| Collagen I Mini-Organo preparation and contraction
• 1% bovine serum albumin (BSA) in PBS. • Fibroblast optimised growth medium (as determined in 2b).
• 25 and 50-mL plastic reservoirs.
• 96-well cell culture-treated plates • Wide, shallow ice tray for keeping plates cool during preparation of Mini-Organos
| Collagen I Mini-Organo invasion
• Stainless steel round screen mesh size 40 (sigma S0770). Each mesh is cut six times at~25-mm intervals, to a depth of 10 mm.
This allows three arms to be bent down creating a platform approximately 3 to 4 mm high (see Figure 1H ) 
| Equipment needed
• 200-μL and 1-mL pipettes (incl. sterile tips).
• Benchtop centrifuge at room temperature.
• Cell counter (automated or haemocytometer).
• Standard tissue culture incubator suitable for cells of interest.
• Stepper pipette*.
• Multichannel pipette*. 3 | EXPERIMENTAL PROCEDURE
| Preparation and quantification of high quality rat tail collagen
i. All work should be carried out using clean, sterile equipment. The use of a laminar flow hood is strongly advised, although not essential. Wash 12 to 14 rail tails (to give a total of 75-100 g of tails) in 70% ethanol, and leave to soak to soften the tails but do not leave for longer than 30 minutes. To remove the collagen-rich tendons, rotate a scalpel blade around the proximal region of the tail, carefully cut the skin of the tail along its length, and peel away the skin from the proximal cut (the skin should come off in one piece).
Using toothed forceps, grip midway between the largest section of the tendon to maximise the tendon removed. Twist the tendon slightly to improve the grip and remove the tendon from the upper sheath, pulling towards the tip of the tail in a controlled movement.
Take care not to remove too much accompanying sheath in the process. Once removed, collect the tendons into fresh MilliQ water. A visual demonstration of the approach has been previously published by Timpson and colleagues. 42 ii. Solubilise the collagen I from the rat tail tendons by transferring vi. Centrifuge the solution at 10 000 rpm at 4°C for 30 minutes. xi. Collagen I concentration should be accurately determined using a kit such as the Sircol collagen quantification kit (BioColor Ltd) or a modified Lowry assay. 52 With high concentrations of collagen, the higher volume of standards should be used and collagen diluted 1:10 or 1:20 to be within range.
xii. Adjust the collagen I concentration to 2.5 mg/mL (or desired concentration) using 0.5 mM acetic acid at 4°C.
xiii. Using a biological safety cabinet or equivalent UV light source, sterilise the collagen I solution for 20 minutes on ice before storing at 4°C. For long-term storage, the solution should be lyophilized and stored at 4°C. Once this collagen stock is established, it is ready for use in the Mini-Organo. It is important to keep the collagen I solution cold at all times to avoid unwanted degradation and polymerisation. A collagen I solution that is not translucent at stage viii will likely be of poor quality. Similarly, a final stock concentration of below 2.5 mg/mL will not be suitable for downstream applications described in this protocol.
| Anticipated results
Higher stock concentrations can be generated, up to 4 to 5 mg/mL and may be necessary for some highly invasive CC lines (such as the fibrosarcoma cell line HT1080) or highly contractile CAFs.
The above protocol should yield approximately 1.0 to 1.5 g of purified acid-extracted collagen I which is enough to produce approximately 30 to 50 separate 96-well plates, equivalent to 3000 to 5000 experimental conditions.
| Preparation of Mini-Organo hydrogels
i. Contraction of the collagen gels is facilitated by ensuring that the gels are free from attachment to the 96-well culture plate. To prevent the Mini-Organo gels sticking to the well, first coat the wells with 1% BSA in sterile PBS for 1 hour in a tissue culture incubator at 37°C (or at 4°C overnight) ( Figure 1B ). Once incubated, remove the PBS/BSA solution and wash briefly with PBS twice before use.
BSA-coated plates can be stored in PBS in the fridge for 24 to 48 hours.
ii. De-gas the collagen I solution under vacuum for 15 minutes. This step is important to prevent the formation of bubbles within the Mini-Organos.
iii. Trypinise fibroblasts/CAFs according to normal passage protocol for your cell line ( Figure 1C ). Count the cells, resuspend in normal growth medium at the required concentration, and keep on ice.
The precise cell number required per Mini-Organo will need to be optimised prior to experimental work (optimisation described below in 3c. Anticipated Results).
iv. For 12 mL of collagen I Mini-Organo mixture (enough for 1× 96well plate at 100 μL per well, including pipetting dead volumes), add the following components carefully and mix, taking care to avoid bubbles ( Figure 1D ). Ensure that the following components are kept on ice. Mix the reagents in a prechilled container on ice, adding the collagen I solution as the last step. Once the collagen I solution is neutralised, it will begin to gel unless kept at 4°C. Figure 1E ). Tip: drawing up and emptying the tip a couple of times will create a small dead volume (5-10 μL). This will allow a more precise volume to be transferred to each well of the plate and, at the same time, avoid the formation of bubbles during pipetting. Pipetting the collagen against the side of the well and allowing it to run down into the well will also reduce the likelihood of generating bubbles.
vi. Allow gels to polymerise for 1 hour in the incubator (37°C). To maintain consistent pore sizes across different experiments, it is essential to ensure a standardised polymerisation protocol [53] [54] [55] (Figure 1F ). xi. To obtain a quantitative measure for the level of Mini-Organo contraction, the relative area of the well and the gel are measured using ImageJ software (as depicted in Figure 2A,B) . The percentage of contraction is calculated using the following formula:
Contraction % ð Þ ¼ 100 × well area-gel area ð Þ well area :
| Anticipated results
The Mini-Organos will set within 1 hour at 37°C at which time the gels should go from clear to slightly opaque ( Figure 1F ). It is important to ensure that the Mini-Organos, once set, are free from bubbles. The best way to ensure this is to de-gas the collagen I solution so that the mixed solution is free from large bubbles. Also, avoid vigorous pipetting because large bubbles will affect contraction and subsequent invasion.
The small size of the Mini-Organo matrices requires a high degree of precision during casting as discrepancies will lead to variations in the degree of contraction. A stepper pipette will improve the accuracy of pipetting; however, a dead volume of 100 to 150 μL should be taken into consideration. In the example illustrated in Figure 2B ,C, we show the effect of changing KPC-CAF number and incubation time on levels of contraction over 72 hours. As would be expected, higher numbers of CAFs seeded within the Mini-Organos lead to a greater rate of contraction, which continues over the 72-hour incubation period. Typically, depending on cell number seeded, the maximal rate of hydrogel contraction occurs within the first 72 hours, after which the rate of contraction will slow and ultimately plateau.
| Stromal cell remodelling of the ECM: Mini-Organo contraction assay
| Anticipated results
The contraction of the fibroblast embedded collagen I plugs should be visible by 24 hours at 37°C after generating the matrices. The degree of contraction will be highly dependent on the initial concentration of CAFs seeded to the matrix ( Figure 2B-2D) , and also the activation status of the fibroblasts/CAFs being used, as well as interventions being applied. Furthermore, the initial starting concentration of collagen will also alter the level of contraction seen at different time points ( Figure 2E ). This combination of factors will ultimately determine the resulting porosity of the final contracted Mini-Organo, and as a result the ability of CCs to invade. 53 If using a fibroblast/CAF line for the first time, an assessment of contractile behaviour should be undertaken and contraction curves generated ( Figure 2C ). This will allow determination of optimal seeding density to reach an approximate 30% to 50% contraction of the plugs prior to seeding of CCs. Typically, no significant additional contraction of the matrix is seen once the gels are transferred to the stainless steel grids at the air-liquid interface (Section 3d: Mini-Organo Invasion Assay).
Analysis of the extent of remodelling by embedded CAFs can be undertaken at this stage. For example, Picrosirius Red staining is a simple and effective way to determine collagen density within the plugs ( Figure 2F ). The specific staining of collagens by Picrosirius red is one of the most important stains to study collagen networks. 56, 57 This approach also has the added advantage that under polarised light, the dye bound collagen fibre bundles appear green, red, or yellow and are easily differentiated from the black background ( Figure 2G [top] ). This allows for a quantitative morphometric analysis of the collagen fibres where the polarised colours reflect fibre thickness and packing ( Figure 2G [top] ). This approach has been applied by us and many other groups to look at collagen fibre remodelling in organotypic studies as well as in normal and diseased tissues. 10, 58, 59 Finally, second harmonic generation (SHG) imaging is a label-free imaging technique that allows imaging of noncentrosymmetric entities such as collagen fibres. The generation of an SHG signal occurs when two photons with the same wavelength fuse into a single photon with half of the original wavelength upon interaction with a non-centrosymmetric entity. This approach allows for high resolution imaging of collagen fibres. Using SHG-generated images, orientation of collagen fibres can be assessed ( Figure 2G [bottom] ). 10, [58] [59] [60] [61] In addition, collagen fibre network organization can also be characterised using grey-level cooccurrence matrix (GLCM) analysis. 10, 58, 59, [61] [62] [63] This method provides a readout of the texture of a sample by quantifying the similarity between pixels across an image 64 (Figure 2H , data example shown is from blebbistatin treated CAFs [ Figure 4B] ). Figure 1H ).
| 3D cancer cell invasion: Mini-Organo invasion assay
Optional step:
The Mini-Organos should sit at the air-liquid interface with the top layer of CCs exposed to the air. In some studies, this may A pilot experiment to optimise the parameters that lead to approximately 50% invasion into the Mini-Organo will allow for testing of inhibitory or stimulatory interventions. In situations where a drug, or drug(s) of interest may take more than 24 hours to act, or may need to be given sequentially on separate days, it will be necessary to optimise invasion conditions to yield a slower rate of invasion to accommodate for this.
| Anticipated results
| Scoring and analysis
To determine the extent of invasion of CCs into the Mini-Organos, they need to be fixed and processed for histological and immunohistochemical analysis. A wide range of readouts including invasion, proliferation, survival, or differentiation can be conducted (see Figure 3 ). viii. In order to determine the invasive index, a score is calculated as the number of cells detected within the whole Mini-organo section divided by the total number of CCs seeded ( Figure 3A ). An alternative and often-used metric is to calculate the invasive index between the noninvaded upper layer of cells (on top of the gel) and the total number of invaded cells. Finally, a third approach is to calculate the area of the "noninvasive" cell layer (on top) and the "invasive area" (from the top layer down to the leading edge of the invasive cells), and normalise the invasive area with total area (noninvasive + invasive). 48 Note: All slides should be stained simultaneously for comparison at the same time to avoid adjusting software parameters for each slide.
Automated nucleus detection parameters are also dependent on magnification.
| Anticipated results
The invasion of CCs into the remodelled collagen plugs can be determined by H&E staining (Figure 3B and 3D-3F) or using a cell specific immunohistochemistry stain for a specific subset, or all CCs using markers such as pan-cytokeratin ( Figure 3C ,G) as we have done previously. 10, 58 Various elements can be changed to determine the effects on CC invasion. For example, standard growth serum (FBS) should drive the invasion of most CCs. Altering FBS levels may affect invasion of some CC lines. In our example, we see that the aggressive KPC CCs invade independent of FBS concentration ( Figure 3D ). Treatment of invaded CCs with various anticancer therapies is facilitated and allows for screening of difference combinations. Here, we show the effects of Blebbistatin on KPC CC invasion ( Figure 3G ) and gemcitabine, the standard-of-care therapy for pancreatic cancer on invaded KPC CC viability. Readouts include measurement of proliferation (Ki67 staining) ( Figure 3H ) and apoptosis (CC3) ( Figure 3I ) using our previously published staining protocols. 10,58
| PRACTICAL APPLICATIONS OF THE MINI-ORGANO IN CANCER BIOLOGY
The traditional organotypic contraction assays previously described 10, 42 typically take 8 to 12 days to contract, and another Red staining, SHG imaging, orientation and alignment analysis, 10, 60 and grey level co-occurrence matrix (GLCM) analysis 10, 58 as examples of a few of the approaches that can be applied ( Figure 2F-2H ).
The contractile phase of the Mini-Organo allows for the rapid con- Figure 2H ). The addition of anticontractile drugs leads to a significant reduction in the contraction of the Mini-Organos ( Figure 4C ) in a dose-dependent manner ( Figure 4B ).
In addition, we evaluated the effects of two YAP/TAZ inhibitors, CAFs are present at all stages of cancer and are believed to be the main cell type responsible for regulating the desmoplastic reaction in cancer. Dissecting the mechanisms underlying CAF activation has received much attention in the last decade. 37, 69 As such, CAFs are believed to be promising targets in cancer. Here, we use our 3D
Mini-Organo to demonstrate that it is an excellent tool to explore the mechanisms behind CAF activation.
Transforming growth factor (TGFβ) is the most potent fibrogenic cytokine known, [70] [71] [72] [73] and it is now well-recognised that TGF-β1 plays an important role in fibroblast activation, proliferation, and fibrotic ECM remodelling. In cancer, sustained CAF activation is partly maintained through autocrine secretion and stimulation of TGF-β1 and SDF-1α. As expected, exogenously added TGF-β1 induces CAF activation and gel contraction of two distinct types of human CAFs (Figure 4 G). Recent work has also demonstrated that prolonged exposure to hypoxia reduces CAF activation and ECM remodelling. 51 We confirmed this finding in our model system (Figure 4H ,I) and further show that hypoxic suppression of CAFs can be rescued by the addition of exogenous TGF-β1 ( Figure 4H,I) . These simple 3D experiments demonstrate that the Mini-Organo is a time-efficient and physiologically relevant model system that can be used not only in drug screens, but also in dissecting molecular mechanisms regulating CAF activation and ECM remodelling and tumour progression.
| CONCLUDING REMARKS
Here, we present a method for the rapid and scalable production of 3D physiologically relevant coculture assays suitable for dissecting both stromal remodelling and CC invasion. One of the major goals in designing 3D physiologically relevant in vitro approaches is to capture the complexity of intercellular communication, nutrient and oxygen gradients, as well as cell polarity and interactions with the ECM that is lacking in more traditional 2D monolayer cultures. The Mini-Organo offers a simple, straightforward, scalable, and cost-effective way of doing this.
Given the enormous number of new anticancer drugs and the accompanying exponentially increasing number of possible drug combinations, the use of in vivo models is prohibitively expensive. Therefore, approaches such as the "Mini-Organo" offer a bridge between the two that allows for higher throughput screening of molecules and interventions within the standard laboratory environment for implementation into the clinic, not only in the cancer field but also many other diseases.
